Yahoo
NYSE - Delayed Quote USD

Labcorp Holdings Inc. (LH)

326.89 -4.61 (-1.39%)
At close: September 4 at 4:00:02 PM EDT
326.89 0.00 (0.00%)
After hours: September 4 at 7:44:32 PM EDT
Trade LH on Coinbase
Chart Range Bar
Loading chart for LH

What's happening with LH?

21m ago
Powered by Yahoo Scout

Labcorp Holdings (LH) recently launched the first FDA-cleared Alzheimer’s blood test, enhancing its diagnostic capabilities. Analysts maintain a Strong Buyconsensus as the company shows strong revenue growth, raising its full-year guidance and benefiting from oncology diagnostics. Upcoming events include an Investor Dayon September 10, 2026, where further strategies will be discussed.

Powered by Yahoo Scout
  • Previous Close 331.50
  • Open 328.00
  • Bid 326.15 x 12000
  • Ask 327.09 x 8000
  • Day's Range 326.16 - 330.54
  • 52 Week Range 244.52 - 341.80
  • Volume 438,649
  • Avg. Volume 678,658
  • Market Cap (intraday) 26.511B
  • Beta (5Y Monthly) 0.85
  • PE Ratio (TTM) 27.02
  • EPS (TTM) 12.10
  • Earnings Date (est.) Nov 3, 2026
  • Forward Dividend & Yield 2.88 (0.87%)
  • Ex-Dividend Date Aug 28, 2026
  • 1y Target Est 341.50

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; a strategic alliance with the National Association of Community Health Centers to support current and emerging clinical leaders through the NACHC Leadership Exchange for Chief Medical Officers; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

www.labcorp.com

71,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

LH
31.26%
S&P 500 (^GSPC)
12.75%

1-Year Return

LH
19.97%
S&P 500 (^GSPC)
18.71%

3-Year Return

LH
63.86%
S&P 500 (^GSPC)
70.93%

5-Year Return

LH
30.85%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 3.73B
Earnings 298.7M
Profit Margin 8.01%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
1B
2B
3B
5.0%
6.0%
7.0%
8.0%

Analyst Insights

View More

Top Analyst

JP Morgan
64/100
Latest Rating
Overweight

Analyst Price Targets

293.00 Low
341.50 Average
326.89 Current
385.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/4/2026
Analyst Piper Sandler
Rating Action Maintains
Rating Neutral
Price Action Raises
Price Target 300 -> 309

Statistics

View More

Valuation Measures

Annual
As of 9/2/2026
  • Market Cap

    26.90B

  • Enterprise Value

    33.52B

  • Trailing P/E

    27.43

  • Forward P/E

    17.18

  • PEG Ratio (5yr expected)

    1.30

  • Price/Sales (ttm)

    1.92

  • Price/Book (mrq)

    3.13

  • Enterprise Value/Revenue

    2.34

  • Enterprise Value/EBITDA

    15.54

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.99%

  • Return on Assets (ttm)

    5.53%

  • Return on Equity (ttm)

    11.73%

  • Revenue (ttm)

    14.35B

  • Net Income Avi to Common (ttm)

    1B

  • Diluted EPS (ttm)

    12.10

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    141.8M

  • Total Debt/Equity (mrq)

    79.12%

  • Levered Free Cash Flow (ttm)

    892.05M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

326.89 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • The major indices are broadly lower at midday on Monday. There's not much good

    The major indices are broadly lower at midday on Monday. There's not much good news out there to celebrate. Renewed strikes between the U.S. and Iran have increased tensions in the Middle East. Oil prices are climbing again. Add to that, Fed Chairman Kevin Warsh hinted last week that rates might be heading higher as inflation stays stubbornly elevated. Crude oil is at $85 per barrel. The yield on the 10-year note is at 4.76%.

  • Raising EPS estimates and target price

    Labcorp operates one of the largest global clinical laboratory networks, providing both routine and specialty testing. It operates in Diagnostics Laboratories and Biopharma Laboratory Services (BLS) segments. BLS supports clinical trial activity for the biopharma industry in approximately 100 countries.

    Rating
    Price Target
  • LabCorp Earnings: Solid Quarterly Performance Leads to Hike in Guidance

    Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.

    Rating
    Price Target
  • LabCorp Earnings: Solid Quarterly Performance Leads to Hike in Guidance

    Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.

    Rating
    Price Target

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: